|
Daily Medical Update
Ovarian cancer
Thursday, June 18, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
JAMA Network Open (2025) - Systematic Review and Meta-Analysis
Key Findings
- Across 4013 patients in 7 randomized trials, first-line PARP maintenance improved progression-free survival in the overall population (HR 0.57, 95% CI 0.46-0.70).
- Progression-free survival improved in BRCA-variant (HR 0.40, 95% CI 0.35-0.45), BRCA wild-type (HR 0.62, 95% CI 0.44-0.86), and HRD-positive tumors (HR 0.44, 95% CI 0.39-0.50), but not in the homologous recombination proficient subgroup.
- No molecular subgroup showed a statistically significant overall survival improvement, while high-grade adverse events were more frequent with PARP inhibitors (HR 2.40, 95% CI 1.16-4.93).
📋 Practice Implication: Use first-line PARP maintenance as a progression-delaying strategy after platinum response, but anchor selection to BRCA and HRD status and expected toxicity because an overall survival gain remains unproven.
|
Gynecologic Oncology (2026) - Time-to-Event Meta-Analysis of Randomized Trials
Key Findings
- Among newly diagnosed patients undergoing interval cytoreductive surgery after neoadjuvant chemotherapy, HIPEC improved progression-free survival (HR 0.65, 95% CI 0.52-0.82) and overall survival (HR 0.68, 95% CI 0.54-0.86).
- In recurrent ovarian cancer, HIPEC did not significantly improve overall survival (HR 0.85, 95% CI 0.69-1.03) or progression-free survival (HR 0.95, 95% CI 0.81-1.12).
- Grade 3 or higher adverse events were not meaningfully increased with HIPEC (45.7% vs 36.4%; RR 1.17, 95% CI 0.87-1.58), and the strongest signal appeared with 90-minute perfusion protocols.
📋 Practice Implication: Reserve HIPEC for carefully selected newly diagnosed patients at interval debulking rather than extrapolating the approach to recurrent disease where benefit remains unconfirmed.
|
Oncology Research (2026) - Meta-Analysis of Randomized Clinical Trials
Key Findings
- Pooling 5 phase III trials with 2296 patients showed no overall survival difference between primary debulking surgery and neoadjuvant chemotherapy followed by interval surgery (RR 0.99, 95% CI 0.94-1.03).
- Disease-free survival was also similar between strategies (RR 0.98, 95% CI 0.95-1.02).
- Subgroup analyses found no significant survival advantage for primary debulking among patients with CC0 resection (RR 0.96, 95% CI 0.87-1.05), FIGO stage III disease (RR 0.97, 95% CI 0.92-1.03), or age under 70 years (RR 1.03, 95% CI 0.97-1.09).
📋 Practice Implication: Choose between primary surgery and neoadjuvant chemotherapy based on resectability, fitness, and institutional capability rather than assuming primary debulking confers superior survival.
|
International Journal of Gynecological Cancer (2025) - Systematic Review and Trial-Level Meta-Analysis
Key Findings
- In 3 randomized trials including 1249 patients, favorable validated selection scores were associated with improved overall survival from secondary cytoreduction plus chemotherapy (HR 0.79, 95% CI 0.66-0.96).
- Complete resection was linked to markedly better overall survival (HR 0.53, 95% CI 0.43-0.64) and progression-free survival (HR 0.51, 95% CI 0.42-0.61) than residual disease.
- Patients with a platinum-free interval of 6 to 12 months showed a significant trend toward overall survival benefit (HR 0.70, 95% CI 0.55-0.91).
📋 Practice Implication: Offer secondary cytoreduction only when validated selection tools and operative assessment suggest a high likelihood of complete gross resection.
|
Annals of Medicine (2026) - Systematic Review and Network Meta-Analysis
Key Findings
- Across 22 randomized trials with 3408 patients, adding bevacizumab, sorafenib, or adavosertib to chemotherapy improved overall survival and progression-free survival versus chemotherapy alone.
- Bevacizumab-containing regimens showed the most consistent efficacy across comparisons, with hazard ratios ranging from 0.52 to 0.65 against chemotherapy alone.
- Adavosertib plus gemcitabine increased grade 3 to 4 adverse events (RR 1.8, 95% CI 1.3-2.7), whereas paclitaxel plus bevacizumab offered the best efficacy-safety balance in the network.
📋 Practice Implication: When treating platinum-resistant disease, favor bevacizumab-based combinations first and treat other targeted doublets as narrower options driven by eligibility and toxicity tolerance.
|
|
💡
Summary
Recent ovarian cancer literature remains practice-facing, with the clearest signals supporting first-line PARP maintenance, selective use of HIPEC after neoadjuvant therapy, and tighter surgical selection in recurrent disease. At the same time, randomized evidence suggests no overall survival advantage for primary debulking over neoadjuvant chemotherapy in unselected advanced disease, and platinum-resistant treatment decisions continue to favor bevacizumab-based combinations over empiric escalation.
|
|